| GEHC |
Report |
Q2 adjusted EPS |
BEAT |
pred ~$1.10 vs. cons $1.041 |
MEDIUM |
| GEHC |
Report |
Q2 revenue |
IN-LINE |
pred ~$5.295B vs. cons $5.267B |
HIGH |
| GEHC |
Report |
Q2 PCS revenue |
MISS |
pred ~$740M vs. cons $750M |
LOW |
| GEHC |
Guide |
FY26 adjusted EPS |
UNCHANGED |
guide $4.80-$5.00 vs. cons $4.881 |
MEDIUM |
| GEHC |
Guide |
FY26 FCF |
LOWER |
guide ~$1.6B vs. cons $1.707B |
MEDIUM |
| GEHC |
Guide |
FY26 organic sales growth |
UNCHANGED |
guide 3%-4% vs. cons UNVERIFIED |
LOW |
| GEHC |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| GEHC |
Return |
5-day cumulative residual |
-2.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — maintained FY outlook leaves implied Q4 risk unresolved |
LOW |